The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography
Bone · 2025
DOI: 10.1016/j.bone.2025.117492 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Bone, 2025. Verfasst von Jamie W Bellinge und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Western Australia, Perth, Western Australia, Australia; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, …. Hauptthemen laut MEDLINE: Bone and Bones, Colchicine, Diabetes Mellitus, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Perth Hospital Medical Research Foundation, Royal Australasian College of Physicians, Kinghorn Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
PURPOSE: Diabetes mellitus (DM) confers an increased risk of fracture. Fracture risk stratification techniques are imperfect, and preventative therapies are sparse. We aimed to describe features associated with a dysfunctional bone metabolism determined by 18F-Sodium Fluoride Positron Emission Tomography (18F-NaF PET) in patients with DM and test the effects of vitamin K1 and colchicine therapy on vertebral 18F-NaF activity. METHODS: This is a post-hoc analysis of a 2 × 2 factorial randomized double-blind placebo-controlled trial. Participants aged 50-80 with DM underwent 18F-NaF PET/CT imaging at baseline, 3 months of therapy with vitamin K1 (10mg/daily) or placebo, and colchicine (0.5 mg/day) or placebo and repeat 18F-NaF PET/CT. The 18F-NaF vertebral mean standardized uptake value (SUVmean) and the CT estimated bone mineral density (BMD) (in Hounsfield units) was evaluated from thoracic vertebra. RESULTS: In total, 149 individuals (66.4 % male, mean age 65.5 ± 6.8 years) were included. Male sex (β -1.421, 95 % CI [-1.826, -1.016], p < 0.001), duration of DM in years (-0.021 [-0.039, -0.002], p = 0.030) and CT estimated vertebral BMD (0.011 [0.006, 0.015], p < 0.001) were independently associated with the SUVmean. The change in the SUVmean was similar between vitamin K1 or placebo groups (-0.07 ± 0.64 v 0.07 ± 0.69, p = 0.20). Participants receiving colchicine therapy had a greater reduction in the SUVmean, compared with placebo (-0.12 ± 0.72 v 0.11 ± 0.60, p = 0.039). CONCLUSION: 18F-NaF PET may be a useful measure of vertebral bone metabolism in people with DM. Three months of oral colchicine reduced the 18F-NaF vertebral SUVmean, whereas Vitamin K1 had no effect. The findings should be considered hypothesis generating. TRIAL REGISTRATION: www.anzctr.org.au (ACTRN12616000024448).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, University of Western Australia, Perth, Western Australia, Australia; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. Electronic address: Jamie.Bell…
- Medical School, University of Western Australia, Perth, Western Australia, Australia; Institute for Nutrition Research, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
- Medical School, University of Western Australia, Perth, Western Australia, Australia; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
- Medical School, University of Western Australia, Perth, Western Australia, Australia.
- Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Medical School, University of Western Australia, Perth, Western Australia, Australia; Cardiometabolic service, Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.
Förderung
- Royal Perth Hospital Medical Research Foundation
- Royal Australasian College of Physicians
- Kinghorn Foundation
Zitieren
APA
Bellinge, J. W., Sim, M., Francis, R. J., Lee, S. C., Chan, D. C., Girgis, C. M., Watts, G. F., Lewis, J. R., & Schultz, C. J. (2025). The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography. Bone. https://doi.org/10.1016/j.bone.2025.117492
Vancouver
Bellinge JW, Sim M, Francis RJ, Lee SC, Chan DC, Girgis CM, et al. The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography. Bone. 2025. doi:10.1016/j.bone.2025.117492
BibTeX
@article{Bellinge2025,
author = {Bellinge, Jamie W and Sim, Marc and Francis, Roslyn J and Lee, Sing Ching and Chan, Dick C and Girgis, Christian M and Watts, Gerald F and Lewis, Joshua R and Schultz, Carl J},
title = {The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography},
journal = {Bone},
year = {2025},
doi = {10.1016/j.bone.2025.117492}
}
EUVIMED